For reference, Seeking Alpha's Quant system is driven by powerful computer processing and SA's special 'Quantamental' ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

Exelixis, Inc. (EXEL) reported mixed results for the second quarter of 2025. Adjusted earnings of 75 cents per share beat the ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Piper Sandler lowered the firm’s price target on Bristol Myers (BMY) to $64 from $66 and keeps an Overweight rating on the shares ahead of ...

Bristol Myers Squibb is taking a strategic leap, offloading five immunology assets, including three in clinical stages, to a ...

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

Research shows that dividends have played a significant role in total equity returns. According to a T. Rowe Price report, dividends have made up nearly one-third of US stock returns since 1926.

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...